Trillium Therapeutics Announces Changes to Its Board of Directors
February 07 2020 - 7:00AM
Trillium Therapeutics Inc. (“Trillium” or the “Company”)
(NASDAQ/TSX: TRIL), a clinical stage immuno-oncology
company developing innovative therapies for the treatment of
cancer, today announced that Paul Walker has been appointed to the
Company’s Board of Directors, and Dr. Ali Behbahani has been
appointed as a Board Observer, effective February 6, 2020.
“We are delighted to welcome Mr. Walker to the
Board of Directors and Dr. Behbahani as a Board Observer, and look
forward to their guidance as we work to bring to patients our CD47
programs,” stated Dr. Robert Kirkman, Executive Chair of Trillium
Therapeutics.
“We are excited about Trillium’s recent progress
and look forward to working with the leadership team as they expand
their clinical development program,” said Paul Walker.
Mr. Walker and Dr. Behbahani are general
partners with New Enterprise Associates (NEA), a global venture
capital firm with more than $20 billion of cumulative committed
capital invested in healthcare and technology companies. Prior to
joining NEA, Paul worked at MPM Capital as a General Partner with
the MPM BioEquities Fund, where he specialized in public, PIPE and
mezzanine-stage life sciences investing. Previously, he was a
portfolio manager at Franklin Templeton Investments. Paul received
a BS in Biochemistry and Cell Biology from the University of
California at San Diego, and holds the Chartered Financial Analyst
(CFA) designation.
Dr. Behbahani’s previous positions include a
consultant in business development at The Medicines Company, a
Venture Associate at Morgan Stanley Venture Partners and as a
Healthcare Investment Banking Analyst at Lehman Brothers. He
concurrently earned his MD degree from The University of
Pennsylvania School of Medicine and his MBA degree from The
University of Pennsylvania Wharton School.
The Company also announced that Dr. Robert Uger,
Trillium’s Chief Scientific Officer has resigned from the
Board of Directors effective February 6, 2020.
About Trillium Therapeutics
Trillium is an immuno-oncology company
developing innovative therapies for the treatment of cancer. The
Company’s two clinical programs, TTI-621 and TTI-622, target
CD47, a “do not eat” signal that cancer cells frequently use to
evade the immune system.
The Company’s pipeline also includes a
preclinical STING (stimulator of interferon genes) agonist program.
As previously announced, the program is earmarked for
out-licensing.
For more information visit:
www.trilliumtherapeutics.com
Caution Regarding Forward-Looking
Information
This press release contains forward-looking
statements within the meaning of applicable United States
securities laws and forward-looking information within the meaning
of Canadian securities laws (collectively, “forward-looking
statements”). Forward-looking statements in this press release
include statements about, without limitation, the belief that
Trillium’s programs could achieve best-in-class status for CD47
blocking agents and Trillium’s future plans and objectives for its
CD47 programs. With respect to the forward-looking statements
contained in this press release, Trillium has made numerous
assumptions regarding, among other things: the effectiveness and
timeliness of clinical trials; and the completeness, accuracy and
usefulness of the data. While Trillium considers these assumptions
to be reasonable, these assumptions are inherently subject to
significant scientific, business, economic, competitive, market and
social uncertainties and contingencies. Additionally, there are
known and unknown risk factors that could cause Trillium’s actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements contained in this press
release. Factors that may cause such a difference include, without
limitation, risks and uncertainties related to the reliance on
positive results of preclinical and early clinical research as such
results are not necessarily predictive of results of later-stage
clinical trials. A further discussion of risks and uncertainties
facing Trillium appears in Trillium’s Form 20-F for the year ended
December 31, 2018 is filed with Canadian securities authorities and
with the U.S. Securities Exchange Commission, each as updated by
Trillium’s continuous disclosure filings, which are available at
www.sedar.com and at www.sec.gov. Forward-looking statements
are not guarantees of future performance and accordingly undue
reliance should not be put on such statements due to the inherent
uncertainty therein. All forward-looking statements herein are
qualified in their entirety by this cautionary statement, and
Trillium disclaims any obligation to revise or update any such
forward-looking statements or to publicly announce the result of
any revisions to any of the forward-looking statements contained
herein to reflect future results, events or developments, except as
required by law.
Company Contact:James
ParsonsChief Financial OfficerTrillium Therapeutics Inc.
416-595-0627 x232james@trilliumtherapeutics.com
Media Contact:Mike BeyerSam
Brown Inc.312-961-2502mikebeyer@sambrown.com
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Apr 2023 to Apr 2024